CPLUS BIOTECH
DEAD

Serial Number

79341951

Owner

CPLUS BIOTECH PTY LTD

Filing Date

Feb 25, 2022

Add to watchlist:

No watchlists yet
View on USPTO

CPLUS BIOTECH Trademark

Serial Number: 79341951

CPLUS BIOTECH is a trademark filed by CPLUS BIOTECH PTY LTD on February 25, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

CPLUS BIOTECH PTY LTD (2 trademarks)

Suite 9A, 88 Brandl Street

Entity Type: 82

Trademark Details

Filing Date

February 25, 2022

Registration Date

Not Registered

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 14, 2024 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Aug 29, 2024 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 29, 2024 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 3, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 15, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Nov 15, 2023 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Aug 28, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Aug 28, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Aug 28, 2023 ABN2
ATTORNEY REVIEW COMPLETED
Jun 7, 2023 ATRV
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
Apr 24, 2023 LIME
REFUSAL PROCESSED BY IB
Mar 6, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 14, 2023 RFCS
REFUSAL PROCESSED BY MPU
Feb 13, 2023 RFRR
LIMITATION OF GOODS RECEIVED FROM IB
Jan 30, 2023 LIMG
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 17, 2022 RFCR
NON-FINAL ACTION WRITTEN
Dec 16, 2022 CNRT
ASSIGNED TO EXAMINER
Dec 9, 2022 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Sep 17, 2022 NREP
APPLICATION FILING RECEIPT MAILED
Jun 14, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 10, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 9, 2022 REPR